|
Back to products
Browse products
Approved anticancer agents
Anticancer agents in trials
Anticancer agents
in preclinical trials
Anticancer molecular libraries
Other drug agents
Drug intermediates
Bio-reagents and biochemicals
|
MedKoo product information:
CC-401
|
MedKoo Code#:
200651
|
|
Name:
CC-401
|
|
CAS#:
862832-38-0
Synonym: CC-401
IUPAC/Chemical name:
|
|
Chemical structure: |
Theoretical analysis
|
|
|
|
|
Availability and price:
This agent is not in stock, which may be available through custom synthesis. To inquire quotation and lead time or to ask questions, please send email to
sales@medkoo.com to describe your needs. A representative
will respond your email shortly. We offer big discount for orders of bulk quantities.
|
|
Quality control
data:
Product will be shipped with
supporting analytical data.
|
|
Information about this agent
|
CC-401 is A second generation ATP-competitive
anthrapyrazolone c-Jun N terminal kinase (JNK) inhibitor with potential
antineoplastic activity. Based on the chemistry of SP600125, another
anthrapyrazolone inhibitor of JNK, CC-401 competitively binds the ATP
binding site of JNK, resulting in inhibition of the phosphorylation of
the N-terminal activation domain of transcription factor c-Jun;
decreased transcription activity of c-Jun; and a variety of cellular
effects including decreased cellular proliferation. Check for
active clinical trials or
closed clinical trials using this agent. (NCI
Thesaurus)
Current developer:
Celgene Corporation
1: Kanellis J, Ma FY, Kandane-Rathnayake R,
Dowling JP, Polkinghorne KR, Bennett BL, Friedman GC, Nikolic-Paterson
DJ. JNK signalling in human and experimental renal ischaemia/reperfusion
injury. Nephrol Dial Transplant. 2010 Apr 5. [Epub ahead of print]
PubMed PMID: 20368303.
2: Ma FY, Flanc RS, Tesch GH, Bennett BL, Friedman GC, Nikolic-Paterson
DJ. Blockade of the c-Jun amino terminal kinase prevents crescent
formation and halts established anti-GBM glomerulonephritis in the rat.
Lab Invest. 2009 Apr;89(4):470-84. Epub 2009 Feb 2. PubMed PMID:
19188913.
3: Flanc RS, Ma FY, Tesch GH, Han Y, Atkins RC, Bennett BL, Friedman GC,
Fan JH, Nikolic-Paterson DJ. A pathogenic role for JNK signaling in
experimental anti-GBM glomerulonephritis. Kidney Int. 2007
Sep;72(6):698-708. Epub 2007 Jun 27. PubMed PMID: 17597698.
4: Ma FY, Flanc RS, Tesch GH, Han Y, Atkins RC, Bennett BL, Friedman GC,
Fan JH, Nikolic-Paterson DJ. A pathogenic role for c-Jun amino-terminal
kinase signaling in renal fibrosis and tubular cell apoptosis. J Am Soc
Nephrol. 2007 Feb;18(2):472-84. Epub 2007 Jan 3. PubMed PMID: 17202416.
5: Uehara T, Bennett B, Sakata ST, Satoh Y, Bilter GK, Westwick JK,
Brenner DA. JNK mediates hepatic ischemia reperfusion injury. J Hepatol.
2005 Jun;42(6):850-9. Epub 2005 Apr 7. PubMed PMID: 15885356.
6: Uehara T, Xi Peng X, Bennett B, Satoh Y, Friedman G, Currin R,
Brenner DA, Lemasters J. c-Jun N-terminal kinase mediates hepatic injury
after rat liver transplantation. Transplantation. 2004 Aug
15;78(3):324-32. PubMed PMID: 15316358.
|
Contact MedKoo:
Email:
sales@medkoo.com
(Keyword; CAS#; MedKoo code#)
|
